Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

BACKGROUND: A large proportion of patients with autosomal dominant polycystic kidney disease (ADPKD) suffers from polycystic liver disease. Symptoms arise when liver volume increases. The somatostatin analogue lanreotide has proven to reduce liver volume in patients with polycystic liver disease. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Gevers, Tom JG, Chrispijn, Melissa, Wetzels, Jack FM, Drenth, Joost PH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368739/
https://www.ncbi.nlm.nih.gov/pubmed/22475206
http://dx.doi.org/10.1186/1471-2369-13-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368739/
https://www.ncbi.nlm.nih.gov/pubmed/22475206
http://dx.doi.org/10.1186/1471-2369-13-17

Ejemplares similares